Current Pharmaceutical Biotechnology
Title: Editorial [Hot Topic: Novel Agents for Multiple Myeloma Treatment (Guest Editors: D. Ribatti and A. Vacca)]
Volume: 7 Issue: 6
Author(s): Domenico Ribatti and Angelo Vacca
Affiliation:
Export Options
About this article
Cite this article as:
Ribatti Domenico and Vacca Angelo, Editorial [Hot Topic: Novel Agents for Multiple Myeloma Treatment (Guest Editors: D. Ribatti and A. Vacca)], Current Pharmaceutical Biotechnology 2006; 7 (6) . https://dx.doi.org/10.2174/138920106779116937
DOI https://dx.doi.org/10.2174/138920106779116937 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
42
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vascular Endothelial Growth Factor Receptor 1, a Therapeutic Target in Cancer, Inflammation and Other Disorders
Current Medicinal Chemistry Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer
Anti-Cancer Agents in Medicinal Chemistry Intracoronary Injection of Drugs to Treat No – Reflow Phenomenon and Microcirculatory Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry Behcets Syndrome: Literature Review
Current Rheumatology Reviews Application of Mesenchymal Stem Cells in Melanoma: A Potential Therapeutic Strategy for Delivery of Targeted Agents
Current Medicinal Chemistry Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience STIP Regulates ERK1/2 Signaling Pathway Involved in Interaction with PP1γ in Lymphoblastic Leukemia
Current Molecular Medicine Molecular Pathogenesis of Philadelphia Chromosome Negative Chronic Myeloproliferative Neoplasms
Current Cancer Drug Targets The Challenges in Moving from Ageing to Successful Longevity
Current Vascular Pharmacology The Mechanisms of Anticancer Agents by Genistein and Synthetic Derivatives of Isoflavone
Mini-Reviews in Medicinal Chemistry Proteasome Inhibition as a New Therapeutic Principle in Hematological Malignancies
Current Drug Targets The Recent Progresses on The Improved Therapy of Melanoma by Novel Drug Delivery Systems
Current Drug Targets Radiation Therapy in the Early 21st Century: Technological Advances
Current Cancer Therapy Reviews RANKL/RANK/OPG: Key Therapeutic Target in Bone Oncology
Current Drug Discovery Technologies Anti-Angiogenic Therapies in the Treatment of Waldenstrom's Macroglobulinemia
Current Cancer Drug Targets Pharmacokinetic Mechanisms for Reduced Toxicity of Irinotecan by Coadministered Thalidomide
Current Drug Metabolism Drug-Mediated Targeted Disruption of Multiple Protein Activities Through Functional Inhibition of the Hsp90 Chaperone Complex
Current Medicinal Chemistry The Cancer Related Thrombotic Tendency in Sepsis
Current Drug Targets Acute Graft-Versus-Host Disease-Challenge for a Broader Application of Allogeneic Hematopoietic Cell Transplantation
Current Stem Cell Research & Therapy Anti-Tumoral Effect of the Non-Nucleoside DNMT Inhibitor RG108 in Human Prostate Cancer Cells
Current Pharmaceutical Design